

# Junichi Soh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1692703/publications.pdf>

Version: 2024-02-01

186  
papers

5,889  
citations

81743

39  
h-index

88477

70  
g-index

189  
all docs

189  
docs citations

189  
times ranked

8516  
citing authors

#	ARTICLE	IF	CITATIONS
1	Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non-“Small Cell Lung Cancer. <i>Cancer Research</i> , 2006, 66, 7854-7858.	0.4	422
2	<i>PIK3CA</i> Mutations and Copy Number Gains in Human Lung Cancers. <i>Cancer Research</i> , 2008, 68, 6913-6921.	0.4	399
3	Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-“like Properties in Cancer Cells. <i>Cancer Research</i> , 2013, 73, 3051-3061.	0.4	241
4	Genetic Predictors of MEK Dependence in Non-“Small Cell Lung Cancer. <i>Cancer Research</i> , 2008, 68, 9375-9383.	0.4	235
5	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7464.	1.1	205
6	Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. <i>PLoS ONE</i> , 2009, 4, e4576.	1.1	177
7	Knockdown of Oncogenic KRAS in Non-“Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 336-346.	1.9	151
8	<i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2009, 124, 1778-1784.	2.3	131
9	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. <i>International Journal of Cancer</i> , 2007, 120, 1239-1247.	2.3	120
10	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In-Vitro Experiments. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1321-1332.	0.5	118
11	Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2011, 17, 4965-4974.	3.2	116
12	Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations. <i>Journal of Thoracic Oncology</i> , 2014, 9, 456-463.	0.5	112
13	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. <i>International Journal of Cancer</i> , 2006, 119, 2353-2358.	2.3	102
14	Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 32-38.	0.9	102
15	Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt338.	3.0	99
16	Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. <i>Lung Cancer</i> , 2012, 77, 162-167.	0.9	86
17	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non-“small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5763-5768.	3.2	81
18	ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. <i>Lung Cancer</i> , 2008, 59, 377-384.	0.9	78

#	ARTICLE	IF	CITATIONS
19	Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung. <i>Journal of Thoracic Oncology</i> , 2008, 3, 340-347.	0.5	78
20	CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1378-1388.	0.5	71
21	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER 2 oncogene alterations. <i>Cancer Science</i> , 2016, 107, 45-52.	1.7	71
22	Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Research</i> , 2019, 17, 499-507.	1.5	65
23	Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 632-637.	0.5	62
24	Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib. <i>Cancer Science</i> , 2015, 106, 1377-1384.	1.7	62
25	Risk Factors for Recurrence and Unfavorable Prognosis in Patients with Stage I Non-small Cell Lung Cancer and a Tumor Diameter of 20 mm or Less. <i>Journal of Thoracic Oncology</i> , 2007, 2, 808-812.	0.5	60
26	Molecular oncology of lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2011, 59, 527-537.	0.4	60
27	Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines. <i>Journal of Thoracic Oncology</i> , 2009, 4, 161-166.	0.5	59
28	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. <i>Oncogene</i> , 2013, 32, 4034-4042.	2.6	59
29	Estimation of age-related DNA degradation from formalin-fixed and paraffin-embedded tissue according to the extraction methods. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 2683-2688.	0.8	58
30	The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. <i>Breast Cancer Research</i> , 2010, 12, R43.	2.2	56
31	Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. <i>Scientific Reports</i> , 2017, 7, 40847.	1.6	54
32	Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. <i>Lung Cancer</i> , 2008, 62, 120-125.	0.9	52
33	Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. <i>Oncology Reports</i> , 2013, 29, 2169-2174.	1.2	46
34	Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. <i>Cancer Science</i> , 2018, 109, 3183-3196.	1.7	46
35	The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. <i>Lung Cancer</i> , 2012, 75, 161-166.	0.9	45
36	The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2013, 82, 485-490.	0.9	43

#	ARTICLE	IF	CITATIONS
37	Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. <i>Oncology Reports</i> , 2003, 10, 1455-9.	1.2	42
38	Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung. <i>Journal of Clinical Oncology</i> , 2007, 25, 3952-3957.	0.8	42
39	Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 26-31.	0.9	42
40	Detection of EGFR Gene Mutations Using the Wash Fluid of CT-Guided Biopsy Needle in NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2008, 3, 472-476.	0.5	38
41	Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2008, 3, 704-710.	0.5	38
42	DV200 Index for Assessing RNA Integrity in Next-Generation Sequencing. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	38
43	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. <i>Cancer Science</i> , 2008, 99, 303-308.	1.7	37
44	Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 409-415.	0.9	37
45	Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness. <i>Neoplasia</i> , 2019, 21, 627-640.	2.3	36
46	Impact of age on epidermal growth factor receptor mutation in lung cancer. <i>Lung Cancer</i> , 2012, 78, 207-211.	0.9	35
47	Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis. <i>International Journal of Cancer</i> , 2019, 145, 569-575.	2.3	35
48	Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1915-1923.	1.3	34
49	EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. <i>Lung Cancer</i> , 2007, 56, 445-448.	0.9	33
50	Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. <i>Oncology Reports</i> , 2013, 29, 133-140.	1.2	33
51	Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. <i>PLoS ONE</i> , 2017, 12, e0171356.	1.1	33
52	Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion. <i>Cancer Letters</i> , 2019, 452, 178-190.	3.2	32
53	Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. <i>International Journal of Cancer</i> , 2007, 121, 1162-1167.	2.3	29
54	Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. <i>Cancer Science</i> , 2018, 109, 1166-1176.	1.7	29

#	ARTICLE	IF	CITATIONS
55	Neuroplastin <sup>2</sup> mediates S100A8/A9-induced lung cancer disseminative progression. <i>Molecular Carcinogenesis</i> , 2019, 58, 980-995.	1.3	28
56	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. <i>Oncology Letters</i> , 2015, 10, 1775-1782.	0.8	27
57	Acquired resistance mechanisms to afatinib in <i>HER2</i> -amplified gastric cancer cells. <i>Cancer Science</i> , 2019, 110, 2549-2557.	1.7	26
58	DNA methylation status of REIC/Dkk-3 gene in human malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 799-809.	1.2	24
59	A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 699-706.	0.5	24
60	Induction Chemoradiotherapy Followed by Surgical Resection for Clinical T3 or T4 Locally Advanced Non-Small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 2685-2692.	0.7	23
61	Radiofrequency Ablation of Lung Tumors Using a Multitined Expandable Electrode: Impact of the Electrode Array Diameter on Local Tumor Progression. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 87-95.	0.2	23
62	Therapeutic strategies for afatinib-resistant lung cancer harboring <i>HER2</i> alterations. <i>Cancer Science</i> , 2018, 109, 1493-1502.	1.7	23
63	Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. <i>Cancer Science</i> , 2018, 109, 3634-3642.	1.7	23
64	Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e87900.	1.1	23
65	Impact of aberrant methylation of microRNA-9 family members on non-small cell lung cancers. <i>Molecular and Clinical Oncology</i> , 2013, 1, 185-189.	0.4	22
66	Predicting pleural invasion using HRCT and 18F-FDG PET/CT in lung adenocarcinoma with pleural contact. <i>Annals of Nuclear Medicine</i> , 2015, 29, 757-765.	1.2	22
67	Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. <i>Scientific Reports</i> , 2016, 6, 39557.	1.6	22
68	Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. <i>Carcinogenesis</i> , 2018, 39, 719-727.	1.3	22
69	Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 66, 107-113.	0.9	20
70	exSSSRs (extracellular S100 soil sensor receptors) fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis. <i>International Journal of Cancer</i> , 2019, 144, 3138-3145.	2.3	20
71	The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. <i>Oncology Reports</i> , 2008, 20, 1265-8.	1.2	20
72	MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells. <i>Anticancer Research</i> , 2012, 32, 4871-5.	0.5	19

#	ARTICLE	IF	CITATIONS
73	Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. <i>Lung Cancer</i> , 2008, 59, 81-87.	0.9	18
74	Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients. <i>Oncology Reports</i> , 2014, 32, 145-152.	1.2	18
75	Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy. <i>Molecular and Clinical Oncology</i> , 2015, 3, 706-712.	0.4	18
76	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 4035.	1.7	18
77	Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. <i>Oncology Reports</i> , 2015, 33, 1499-1504.	1.2	17
78	Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients. <i>Japanese Journal of Radiology</i> , 2017, 35, 61-67.	1.0	17
79	Survival Outcomes of Treatment with Radiofrequency Ablation, Stereotactic Body Radiotherapy, or Sublobar Resection for Patients with Clinical Stage I Non-Small-Cell Lung Cancer: A Single-Center Evaluation. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1044-1051.	0.2	16
80	Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 555-562.	1.3	16
81	Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. <i>Acta Medica Okayama</i> , 2014, 68, 23-6.	0.1	16
82	Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer. <i>Surgery Today</i> , 2015, 45, 1121-1126.	0.7	15
83	Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 14, 4349-4354.	0.8	15
84	Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. <i>Oncology Letters</i> , 2019, 17, 2729-2736.	0.8	15
85	YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers. <i>Cancer Science</i> , 2020, 111, 849-856.	1.7	15
86	Activity of tarloxotinib in cells with EGFR exon20 insertion mutations and mechanisms of acquired resistance. <i>Thoracic Cancer</i> , 2021, 12, 1511-1516.	0.8	15
87	Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. <i>Acta Medica Okayama</i> , 2014, 68, 191-200.	0.1	15
88	Active Secretion of Dimerized S100A11 Induced by the Peroxisome in Mesothelioma Cells. <i>Cancer Microenvironment</i> , 2016, 9, 93-105.	3.1	14
89	Droplet digital PCR as a novel system for the detection of microRNA-34b/c methylation in circulating DNA in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2019, 54, 2139-2148.	1.4	14
90	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). <i>Clinical Lung Cancer</i> , 2021, 22, 596-600.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	14
92	A Case of Delayed Massive Hemothorax Caused by the Rupture of a Pulmonary Artery Pseudoaneurysm after Radiofrequency Ablation of Lung Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 646-649.	0.6	13
93	Sacrificing the pulmonary arterial branch to the spared lobe is a risk factor of bronchopleural fistula in sleeve lobectomy after chemoradiotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 568-572.	0.6	13
94	Clinicopathological characteristics and lymph node metastasis pathway of non-small-cell lung cancer located in the left lingular division. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 791-796.	0.5	13
95	Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. <i>Oncogenesis</i> , 2018, 7, 11.	2.1	13
96	Adjuvant therapy of operable nonsmall cell lung cancer: an update. <i>Current Opinion in Oncology</i> , 2021, 33, 47-54.	1.1	13
97	Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma. <i>Acta Medica Okayama</i> , 2011, 65, 179-84.	0.1	13
98	Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non-Small-Cell Lung Cancers. <i>Clinical Lung Cancer</i> , 2012, 13, 488-493.	1.1	12
99	Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system. <i>Oncology Reports</i> , 2017, 37, 3100-3106.	1.2	12
100	Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. <i>BMC Cancer</i> , 2019, 19, 1144.	1.1	12
101	Validity of using lobe-specific regional lymph node stations to assist navigation during lymph node dissection in early stage non-small cell lung cancer patients. <i>Surgery Today</i> , 2014, 44, 2028-2036.	0.7	11
102	Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001. <i>International Journal of Clinical Oncology</i> , 2017, 22, 274-282.	1.0	11
103	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. <i>Biomolecules</i> , 2019, 9, 456.	1.8	11
104	Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer. <i>Surgery Today</i> , 2020, 50, 1427-1433.	0.7	11
105	Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1767-1775.	0.5	10
106	The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas. <i>Surgery Today</i> , 2021, 51, 127-135.	0.7	10
107	Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies. <i>Anticancer Research</i> , 2017, 37, 301-308.	0.5	10
108	Takotsubo cardiomyopathy associated with pulmonary resections after induction chemoradiotherapy for non-small cell lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2012, 60, 599-602.	0.4	9

#	ARTICLE	IF	CITATIONS
109	Density of Tumor-Infiltrating FOXP3+ T Cells as a Response Marker for Induction Chemoradiotherapy and a Potential Prognostic Factor in Patients Treated with Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2014, 20, 980-986.	0.3	9
110	Primary pulmonary melanoma: a report of two cases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 274.	0.8	9
111	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0129838.	1.1	9
112	Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100938.	0.2	9
113	The prognostic nutritional index is correlated negatively with the lung allocation score and predicts survival after both cadaveric and living-donor lobar lung transplantation. <i>Surgery Today</i> , 2021, 51, 1610-1618.	0.7	9
114	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. <i>Lung Cancer</i> , 2021, 154, 84-91.	0.9	9
115	Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. <i>Acta Medica Okayama</i> , 2013, 67, 19-24.	0.1	9
116	Bronchoplasty to adjust mismatches in the proximal and distal bronchial stumps during bronchial sleeve resection of the left lower lobe and lingular division. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 182-183.	0.6	8
117	Use of a vessel sealing system versus conventional electrocautery for lung parenchymal resection: a comparison of the clinicopathological outcomes in porcine lungs. <i>Surgery Today</i> , 2014, 44, 540-545.	0.7	8
118	Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 741-747.	0.6	8
119	Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy. <i>Surgery Today</i> , 2019, 49, 601-609.	0.7	8
120	The impact and role of EGFR gene mutation on non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 25-31.	1.1	7
121	The allelic distribution of a single nucleotide polymorphism in the PDCD5 gene locus of Japanese non-small cell lung cancer patients. <i>Molecular Medicine Reports</i> , 2008, 1, 667-71.	1.1	7
122	Intrathoracic irrigation with arbekacin for methicillin-resistant <i>Staphylococcus aureus</i> empyema following lung resection. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 15, 437-441.	0.5	7
123	The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy. <i>Annals of Thoracic Surgery</i> , 2016, 102, 985-992.	0.7	7
124	The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells. <i>Oncology Letters</i> , 2016, 11, 3308-3316.	0.8	7
125	Prognostic nutrition index affects the prognosis of patients undergoing trimodality therapy for locally advanced non-small cell lung cancer. <i>Surgery Today</i> , 2020, 50, 1610-1618.	0.7	7
126	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3659-3670.	1.3	7



#	ARTICLE	IF	CITATIONS
127	Genetic alterations in lung adenocarcinoma with a micropapillary component. <i>Molecular and Clinical Oncology</i> , 2016, 4, 195-200.	0.4	6
128	Early postoperative complications after middle lobe-preserving surgery for secondary lung cancer. <i>Surgery Today</i> , 2017, 47, 601-605.	0.7	6
129	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. <i>Lung Cancer</i> , 2020, 148, 100-104.	0.9	6
130	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic <i>BRAF</i> Mutation. <i>Anticancer Research</i> , 2020, 40, 2667-2673.	0.5	6
131	Pulmonary aspergillosis as a late complication after surgery for locally advanced non-small cell lung cancer treated with induction chemoradiotherapy. <i>Surgery Today</i> , 2020, 50, 863-871.	0.7	6
132	A Simple Prognostic Benefit Scoring System for Sarcoma Patients with Pulmonary Metastases: Sarcoma Lung Metastasis Score. <i>Annals of Surgical Oncology</i> , 2021, 28, 3884-3890.	0.7	6
133	Diagnostic Value of Dual-time-point F-18 FDG PET/CT and Chest CT for the Prediction of Thymic Epithelial Neoplasms. <i>Acta Medica Okayama</i> , 2017, 71, 105-112.	0.1	6
134	Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. <i>Acta Medica Okayama</i> , 2018, 72, 507-513.	0.1	6
135	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. <i>Journal of Thoracic Oncology</i> , 2007, 2, 321-324.	0.5	5
136	Contralateral pneumothorax in bullous lung after pneumonectomy: report of two cases. <i>General Thoracic and Cardiovascular Surgery</i> , 2013, 61, 35-37.	0.4	5
137	Fever after lung radiofrequency ablation: Prospective evaluation of its incidence and associated factors. <i>European Journal of Radiology</i> , 2015, 84, 2202-2209.	1.2	5
138	Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin. <i>Annals of Thoracic Surgery</i> , 2017, 104, 971-978.	0.7	5
139	Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients. <i>Anticancer Research</i> , 2020, 40, 4419-4423.	0.5	5
140	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. <i>Clinical Lung Cancer</i> , 2021, 22, e141-e145.	1.1	5
141	The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. <i>Surgery Today</i> , 2021, 51, 1480-1487.	0.7	5
142	Restrictive ventilatory impairment is associated with poor outcome in patients with cT1aN0M0 peripheral squamous cell carcinoma of the lung. <i>Journal of Thoracic Disease</i> , 2017, 9, 4325-4335.	0.6	5
143	Surgical therapy for pulmonary metastasis of breast cancer. <i>Translational Cancer Research</i> , 2020, 9, 5044-5052.	0.4	5
144	The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas. <i>Oncology Reports</i> , 1994, 20, 1265.	1.2	4

#	ARTICLE	IF	CITATIONS
145	Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 3076-3086.	0.6	4
146	Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracilâ€“tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1367-1376.	1.0	4
147	Continuing surgical education of non-technical skills. <i>Annals of Medicine and Surgery</i> , 2020, 58, 177-186.	0.5	4
148	Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 112, 279-288.	0.7	4
149	Adult Mesenchymal Hamartoma of the Chest Wall: Report of a Case. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2014, 20, 663-665.	0.3	3
150	Massive Subcutaneous and Mediastinal Emphysema with Little Pneumothorax Treated by Surgery after Pulmonary Radiofrequency Ablation. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 548-551.	0.9	3
151	A Case of Carcinoma Showing Thymus-Like Differentiation with a Rapidly Lethal Course. <i>Case Reports in Oncology</i> , 2014, 7, 840-844.	0.3	3
152	DNA copy number gains in malignant pleural mesothelioma. <i>Oncology Letters</i> , 2015, 10, 3274-3278.	0.8	3
153	Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma. <i>Oncology Letters</i> , 2016, 11, 705-712.	0.8	3
154	Is tumor location an independent prognostic factor in locally advanced non-small cell lung cancer treated with trimodality therapy?. <i>Journal of Thoracic Disease</i> , 2017, 9, E489-E491.	0.6	3
155	Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 287-290.	0.6	3
156	Myoepithelioma occurring in the posterior mediastinum harboring EWSR1 rearrangement: a case report. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 851-854.	0.6	3
157	Long-term outcomes of pneumonectomy, back-table lung preservation, double-sleeve resection and reimplantation for advanced central lung cancer: the Oto procedure. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 213-214.	0.6	3
158	Chemoradiation therapy for non-small cell lung cancer exacerbates thoracic aortic calcification determined by computed tomography. <i>Heart and Vessels</i> , 2020, 35, 1401-1408.	0.5	3
159	Effectiveness of scheduled intravenous acetaminophen in the postoperative pain management of video-assisted thoracic surgery. <i>Surgery Today</i> , 2021, 51, 589-594.	0.7	3
160	Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301. <i>BMC Cancer</i> , 2021, 21, 506.	1.1	3
161	Frequent EGFR mutations and better prognosis in positron emission tomography-negative, solid-type lung cancer. <i>Clinical Lung Cancer</i> , 2021, , .	1.1	3
162	Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies. <i>Oncology Letters</i> , 2012, 3, 401-404.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Resection of the entire first rib for fibrous dysplasia using a combined posterior-transmanubrial approach. <i>General Thoracic and Cardiovascular Surgery</i> , 2012, 60, 584-586.	0.4	2
164	Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2018, 24, 131-138.	0.3	2
165	Study about the Efficacy of Metformin to Immune Function in Cancer Patients. <i>Acta Medica Okayama</i> , 2016, 70, 327-30.	0.1	2
166	Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 175.	1.1	1
167	Pulmonary resection in a prone position for lung cancer invading the spine. <i>General Thoracic and Cardiovascular Surgery</i> , 2020, 68, 298-301.	0.4	1
168	Mechanisms and Overcome of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Japanese Journal of Lung Cancer</i> , 2012, 52, 131-135.	0.0	1
169	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. <i>Lung Cancer</i> , 2021, 162, 79-85.	0.9	1
170	Presence of a Ground-glass Opacity Component is the True Prognostic Determinant in Clinical Stage I Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100321.	0.6	1
171	Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient. <i>Acta Medica Okayama</i> , 2016, 70, 63-5.	0.1	1
172	Usefulness of Thoracoscopic Debridement for Chronic Empyema after an Extrapleural Pneumonectomy. <i>Acta Medica Okayama</i> , 2016, 70, 507-510.	0.1	1
173	Association between Histological Types and Enhancement of Dynamic CT for Primary Lung Cancer. <i>Acta Medica Okayama</i> , 2020, 74, 129-135.	0.1	1
174	Pulmonary Enteric Adenocarcinoma Harboring a BRAF G469V Mutation.. <i>Acta Medica Okayama</i> , 2021, 75, 759-762.	0.1	1
175	A Case of Pancreatic Adenocarcinoma With Novel K-Ras Mutation and Long Term Survival. <i>American Journal of Gastroenterology</i> , 2002, 97, 1852-1853.	0.2	0
176	Molecular Biology of Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2010, 50, 329-341.	0.0	0
177	P2.02-035 The Advantage of Induction Chemoradiotherapy in Bronchoplastic Procedure for Non-Small Cell Lung Cancer Accompanied with Central Disease Region. <i>Journal of Thoracic Oncology</i> , 2017, 12, S868-S869.	0.5	0
178	P2.02-054 Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017, 12, S880-S881.	0.5	0
179	Effects of Cold Ischemia on RNA Stability and Quality of Lung Tissues Based on Standard PReanalytical Code Categorization. <i>Biopreservation and Biobanking</i> , 2017, 15, 484-486.	0.5	0
180	Intra-tumor and inter-tumor heterogeneity in MET exon 14 skipping mutations and co-mutations in pulmonary pleomorphic carcinomas. <i>Clinical Lung Cancer</i> , 2021, , .	1.1	0

#	ARTICLE	IF	CITATIONS
181	EGFR 変異陽性肺癌に対する Uracil-Tegafur 併用療法の有効性に関する検討。岡山大学医学部呼吸器内科学。岡山大学医学部呼吸器内科学雑誌, 2009, 49, 409-415.		
182	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415.	0.0	0
183	Perioperative Treatment for the Eradication of Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 891-894.	0.0	0
184	Ectopic cervical thymoma: a case report with 18F-fluorodeoxyglucose positron emission tomography findings. Acta Medica Okayama, 2012, 66, 357-61.	0.1	0
185	A Giant Thymic Cyst Accompanied by Acute Mediastinitis. Acta Medica Okayama, 2020, 74, 431-433.	0.1	0
186	Successful Bronchoscopic Treatment for Postoperative Bronchopleural Fistula Using N-butyl-2-cyanoacrylate (NBCA): Report of a Post-completion Pneumonectomy Case with a History of Induction Chemoradiotherapy Followed by Bilobectomy for Advanced Lung Cancer. Acta Medica Okayama, 2021, 75, 91-94.	0.1	0